Heart Failure

Regulatory Matters Related to Monitoring Devices

36 min.

Regulatory Issues Related to the Introduction of New Percutaneous Pumps

36 min.

Inclusion Criteria and Endpoints for Trials of Devices to Treat ADHF

37 min.

New Endpoints and Experimental Designs for Devices for Chronic Heart Failure (Breakthrough)

31 min.

Measuring Health Equity in Clinical Settings: Tips for Healthcare Leaders

9 min.

Reach, Access, and Affordability: Implementing Therapies for All

12 min.

Designing Clinical Trials to Facilitate Better Implementation: Tips for Researchers

12 min.

Leveraging Remote Patient Monitoring to Implement GDMT

15 min.

Amyloidosis Is Everywhere: Is It Really a Rare Disease?

18 min.

How Can We Find Cardiac Amyloidosis Not Amyloid Early?

16 min.

The Importance of Optimizing Medical Therapy in Patients Undergoing Coronary and Structural Interventional Procedures

18 min.

AI in Cardiac Imaging: What is Hidden in the CT and Radiograph?

8 min.

It's All in Front of Our Eyes: How to Exploit EMR in the Heart Failure Management

8 min.

AI: What Does All of This Mean for Heart Failure Patients and Doctors

8 min.

A Multidisciplinary Approach to a Patient With Cardiac Mass: LV Biopsy With Transeptal Approach to Diagnose Melanoma.

13 min.

Avoiding Treatment In Hospital With Furoscix To Manage Congestion At Home: A Pilot Study

12 min.

Does Obesity Paradox Exist in Cardiogenic Shock?

10 min.

Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre Cardiogenic Shock

12 min.

Ventricular Load: Five Decades of Fundamental Cardiovascular Physiology and Biology

12 min.

Ventricular Unloading and Reverse Remodeling in Heart Failure

26 min.

Unloading as a Bridge to Native Heart Recovery in Advanced Heart Failure

9 min.

Unloading as a Bridge to Native Heart Recovery in Advanced Heart Failure: A Glimpse Into the Future

20 min.

EKG in the Screening, Diagnosis and Management of Heart Failure

8 min.

AI in Cardiac Imaging: What is Hidden Behind the ECHOCARDIOGRAPHIC Image?

8 min.

Physiological Modeling at Rest and Exercise of a Novel Right-to-Right Cardiac Shunt

15 min.

The Lymphatic System and The Role in Heart Failure

13 min.

Novel Imaging Methods and Interventions of the Lymphatic System

13 min.

Lessons Learned from Fontan Patients Relevant to Heart Failure

15 min.

Harnessing the Lymphatic System the Treat Heart Failure

23 min.

Clinical Feasibility of a Novel Right-to-Right Cardiac Shunt in Pulmonary Hypertension using Off-the-Shelf Devices

12 min.

Assessing RV Function and RV-PA Coupling in the Contemporary Era: The Gold Standard Approach - PV Loops

7 min.

Assessing RV Function and RV-PA Coupling in the Contemporary Era: Clinical Assessment (Let's Be Practical)

8 min.

Assessing RV Function and RV-PA Coupling in the Contemporary Era: Novel Applications of Invasive RV PV Loops

7 min.

Assessing RV Function and RV-PA Coupling in the Contemporary Era: Noninvasive RV PV Loops

8 min.

How to Determine When the RV Becomes the Problem in PAH

9 min.

Why Invasive Cardiopulmonary Exercise Testing; What is the Added Value?

10 min.

Technical Aspects of Doing Supine Exercise Testing in the Cath Lab

10 min.

Technical Aspect of Doing Upright Exercise Testing

11 min.

How to Optimize “Usable” Hemodynamic Tracings During Exercise: Tips/Tricks, Do's and Don'ts

9 min.

Can High Quality Hemodynamic Exercise Test Be Performed by a Majority of Heart Failure and Interventional Cardiologists?

10 min.

What Limits Exercise Tolerance in Heart Failure: The Big Picture

12 min.

Lessons Learned from Exercise Studies of LVAD Patients

11 min.

HFpEF: Beyond Pulmonary Capillary Wedge Pressure

10 min.

Deep Dive: The Role of the Heart in Limiting Exercise Tolerance

11 min.

Diagnosis and Classification of Pulmonary Hypertension in 2023

11 min.

Monitoring Devices in Pulmonary Hypertension - Moving Beyond CHAMPION

10 min.

Shunt Devices in Pulmonary Hypertension Management

10 min.

Pulmonary Artery Denervation: Innovative Pulmonary Hypertension Therapies

9 min.

BPA in CTEPH Management

10 min.

PYP Scintigraphy is Insufficient as a Non-Invasive Diagnostic Tool: Time for PET!

8 min.

Dichotomizing ATTR-CA Into Neurologic and Cardiac Phenotypes Is So 2010..What Works For One Works For the Other

7 min.

Will Gene Therapy With CRISPR Cure ATTR-CA?

9 min.

NeuroCardiology: Tapping the Nervous System to Understand and Treat Heart Failure

10 min.

Exercise Capacity and Health-Related Quality of Life With Furoscix:  Data From the AT HOME Pilot Study

8 min.

Are We Ready to Start Systematic Screening for ATTR-CA? AS Early Diagnosis is Key

7 min.

Heart Failure Journal Editors' Forum: JACC: Basic to Translational Science

7 min.

Heart Failure Journal Editors' Forum - Circ: Heart Failure

6 min.

Heart Failure Journal Editors' Forum: JACC - Heart Failure

7 min.

Heart Failure Journal Editors' Forum - JACC: Clinical Electrophysiology

7 min.

Heart Failure Journal Editors' Forum: Structural Heart

7 min.

Influence of Serum Potassium on the Decongestive Potential of Spironolactone: Insights from the ATHENA-HF Trial

9 min.

Biological vs Physical Reverse Remodeling in Heart Failure: Implications for Device-Based Therapies for HFrEF

10 min.

Heart Failure Journal Editors' Forum: Journal of Heart and Lung Transplant

8 min.

Heart Failure Journal Editors' Forum: JCF

7 min.

The Projected Burden of Heart Failure

8 min.

A Payors Perspective: Innovative Models to Reduce Cost

9 min.

Who Bears the Cost of Innovation?

9 min.

Medicare Coverage and Postmarket Evidence on Emerging Cardiovascular Devices

8 min.

Are All Incentives Altruistic?: The Importance of Measurement

8 min.

Now is Not Soon Enough: Why Improving Patient Diversity in HF Trials is a Key Priority

10 min.

FDA Guidance on Meaningful Representation in Clinical Trials

22 min.

Training Investigators to Advance Diversity and Inclusion

9 min.

Recruitment Strategies for Vulnerable and Marginalized Trial Participants

9 min.

The Leaders of the Pack: Why Improving Investigator Diversity in Heart Failure Trials is a Key Priority

17 min.

Guideline Directed Medication Therapies (GDMT): Decreasing Time From Initiation to Core Therapy Use

11 min.

GDMT: Overcoming Polypharmacy

9 min.

The Role of Nurses, APPs, and Pharmacists to Optimize Population Heath Heart Failure Outcomes: The Hospital Heart Failure System Perspective

9 min.

Optimizing Euvolemia as Part of GDMT

11 min.

Guideline Directed Medication Therapies (GDMT): Decreasing Time From Initiation to Core Therapy Use - Case Presentation

20 min.

Advanced Heart Failure in ACHD - How Do We Define It?

15 min.

What's the Status of Advanced Heart Failure Care in ACHD Now? MCS, Listing Status and Outcomes

16 min.

How Do We Improve Advanced Heart Failure Outcomes in ACHD? ACTION Learning Network

17 min.

Applications of Gene Therapy in Cardiomyopathies

14 min.

The Multiverse of HFpEF: All Roads Lead to Functional Limitation

9 min.

New Insights Into the Pathophysiology of HFpEF

9 min.

Medical Therapies Work for HFpEF: What, When, How

8 min.

Interventional Therapies for HFpEF

9 min.

Does this patient have HFpEF and if so how to treat? - Mystery Case 1

14 min.

Does this patient have HFpEF and if so how to treat? - Mystery Case 2

9 min.

Medical Therapies of Decompensated Heart Failure and the Concept of "Diuretic Resistance"

8 min.

Debate: Revascularization in Chronic Heart Failure after REVIVED - is GDMT enough?!

4 min.

Debate: Revascularization in Chronic Heart Failure after REVIVED - Revascularize!

5 min.

Revascularization or Medical Therapy in Chronic Heart Failure - Case Resolution

3 min.

Case Presentation: Advanced Heart Failure Patient With Mitral Regurgitation: Edge-to-Edge Repair Versus Transplant/LVAD

3 min.

Case Presentation: Advanced Heart Failure Patient With Mitral Regurgitation: Edge-to-Edge Repair Versus Transplant/LVAD - Mitraclip!

5 min.

Case Presentation: Advanced Heart Failure Patient With Mitral Regurgitation: Edge-to-Edge Repair Versus Transplant/LVAD - Tx/VAD

5 min.

Case Resolution: Advanced Heart Failure Patient With Mitral Regurgitation: Edge-to-Edge Repair Versus Transplant/LVAD

1 min.

Medical Therapies for Heart Failure: The Foundation of Foundational Therapies for Heart Failure

12 min.

Medical Therapies for Heart Failure: Beyond the Four Foundational Therapies: Vericiguat and Omecamtiv Mecarbil

13 min.

The Role of Monitoring Devices in Optimizing Medical Heart Failure Therapies

13 min.

Emerging Medical Pathways for Heart Failure Therapies

13 min.

Opening Talk: Innovation and Technologies to Enhance the Care of Patients With Heart Failure

5 min.

The Impact of SGLT2 Inhibitors Across the Spectrum of Heart Failure

11 min.

SGLT2 Inhibitors Have a Unique Mechanism That Accounts for Their Comprehensive Benefits

16 min.

Contemporary Implementation of Guideline-Directed Therapy for Heart Failure

11 min.

Recent Advances in the Medical Treatment of Patients With Decompensated Heart Failure

9 min.

The AI Revolution and How It Is Impacting Health Care Delivery in Heart Failure

16 min.

Assessing the Residual Risk: What Gaps Should New Technologies Fill?

8 min.

Latest Data From REVIVED

7 min.

Revascularization or Medical Therapy in Chronic Heart Failure - Case Presentation

3 min.

SPOTLIGHT LECTURE: The Importance of Optimizing Heart Failure Therapies in the HF Patient Undergoing Structural Interventions

16 min.

Case Presentation: Management of Advanced HF in a Patient with Severe Secondary MR

5 min.

Use of Artificial Intelligence and Machine Learning to Improve Outcomes of Patients With HF

9 min.

What Interventionalist/Structuralists Should Know About the US Guidelines for Medical Therapies for Heart Failure

6 min.